Satu Mustjoki - Curriculum Vitae#

Education:

• 2011 Adj. professor (docent), Experimental hematology, University of Helsinki (UH)
  
• 2008 Specialist in Clinical Chemistry, UH
  
• 2001 PhD, UH, PhD Thesis with honor
  
• 1997 MD, UH

Funding (2017 - present)

Erkko Foundation, 2023-2026 1 636K €; Leukemia and Lymphoma society, 2023-2026 750K € (Co-PI with Dr. C. Mitsiades), Academy of Finland (AoF) and NIH joint funding, 2023-2027 750K €; AoF Terva (Consortium PI), 2018 - 2022 830 524€; AoF project funding, 2020 - 2024 752 866€; Business Finland Cancer IO consortium 2020-2022 430 613€; Pfizer investigator initiated grant 2020 - 2022 298 179€; AoF Covid-19 special funding 2020 - 2022 277 958 €; Special Funding for University level Health Research 2014 - 2023 657K €; ERC consolidator grant 2015-2020 2 047K €; ERC proof-of-concept grant 2020 - 2021 150K €; Finnish Cancer Organizations 2017 - 2025 1 350K €; Sigrid Juselius Foundation 2017-2023 495K €; Nordic Cancer Union 2019 - 2021 195K €; EraPerMed (consortium PI) 2019 - 2021 566 217€ (whole consortium 1 562 420€); Pfizer investigator initiated grant (IIG) 2019 - 2024, 44K €; HiLife Fellow 2017 - 2025 330K €; Novartis IIG 2017 - 2022 689K €

Supervision and leadership

• Leader: Scientific director of iCAN Digital Precision Cancer Medicine Flagship, UH, 2022-2026, Director of Translational Immunology research program, UH, 2019-2025; Consortium PI Heal-Art Academy of Finland Terva project 2018-2022; Consortium PI EraPerMed EU project 2019-2022
  
• Supervisor
  
  • Post-Doctoral studies: 9 completed + 9 in progress
    
  • PhD thesis: 18 completed + 13 ongoing
    
  • MSc and MD thesis: 22 completed

Key academic merits

• 2023 - present Member of scientific committee of European School of Hematology
  
• 2022 Deputy member of the Faculty of Medicine Faculty council, UH
  
• 2021 - present Member of scientific program committee of European Hematology Assoc
  
• 2018 Board member of the Faculty of Medicine Research council, UH
• 2016 - 2021Chair, Vice chair and member of the American Soc. of Hematol. (ASH) myeloid neoplasia scientific committee
  
• 2010 - present Board member of the Nordic CML study group, Finnish Publication forum promoting open science (2018 - 2021)
  
• 2009 - present PI or study steering group member (3) and subinvestigator (24) in international academic clinical studies (2009 - present), PI in 9 international biomarker programs